Patents by Inventor Daniela Stoellner

Daniela Stoellner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TO MODIFIED HUMAN IGF-1/E PEPTIDES
    Publication number: 20140243265
    Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 28, 2014
    Applicant: NOVARTIS AG
    Inventors: Mara FORNARO, John XU, Yuan GAO, Rainer HILLENBRAND, Francois LEGAY, Daniela STOELLNER
  • Antibodies to modified human IGF-1/E peptides
    Patent number: 8753632
    Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: June 17, 2014
    Assignee: Novartis AG
    Inventors: Mara Fornaro, John Xu, Yuan Gao, Rainer Hillenbrand, Francois Legay, Daniela Stoellner
  • ANTIBODIES TO MODIFIED HUMAN IGF-1/E PEPTIDES
    Publication number: 20110218145
    Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.
    Type: Application
    Filed: November 10, 2009
    Publication date: September 8, 2011
    Applicant: NOVARTIS AG
    Inventors: Mara Fornaro, John Xu, Yuan Gao, Rainer Hillenbrand, Francois Legay, Daniela Stoellner
  • Polysaccharide-peptide conjugates for use as thrombin substrates
    Patent number: 7691641
    Abstract: The present invention relates to macromolecular polysaccharide-peptide conjugates which contain a peptide portion which C-terminally contains the amino acid sequence Ala-Gly-Arg, which is cleaved by thrombin.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: April 6, 2010
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Daniela Stoellner, Thilo Henckel
  • Polysaccharide-peptide conjugates for use as thrombin substrates
    Publication number: 20080076183
    Abstract: The present invention relates to macromolecular polysaccharide-peptide conjugates which contain a peptide portion which C-terminally contains the amino acid sequence Ala-Gly-Arg, which is cleaved by thrombin.
    Type: Application
    Filed: July 30, 2007
    Publication date: March 27, 2008
    Applicant: Dade Behring Marburg GmbH
    Inventors: Daniela Stoellner, Thilo Henckel